Alterity Therapeutics Ltd

Alterity Therapeutics Limited is a biotechnology company focused on research and development for Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. Its lead drug candidate, ATH434, is a small molecule that has completed a Phase II clinical trial for Parkinson's disease. The company is also developing ATH434-201 and ATH434-202, both in Phase II trials for early-stage and general MSA, respectively, along with bioMUSE, a biomarker program for MSA progression. It operates a drug discovery platform that generates patentable chemical compounds targeting the underlying pathology of neurological diseases. Formerly known as Prana Biotechnology Limited, it changed its name to Alterity Therapeutics Limited in April 2019. Incorporated in 1997, the company is based in Melbourne, Australia.